| Cat.No. | Name | Information |
|---|---|---|
| M3887 | SB225002 | SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM and >150-fold selectivity over CXCR1 and four other 7-TMRs. |
| M5160 | Reparixin | Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors with IC50 of 1 and 100 nM, respectively. |
| M1898 | Plerixafor (AMD3100) | Plerixafor (AMD3100) is a CXCR4 chemokine receptor antagonist. |
| M3769 | Plerixafor 8HCl | Plerixafor 8HCl (AMD3100 8HCl) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
| M2381 | AMD3465 hexahydrobromide (AMD3465 ) | AMD3465 hexahydrobromide（AMD3465 ) is an effective CXCR4 antagonist that inhibits 12G5 mAb in SupT1 cells. The IC50 values of CXCL12AF647 and CXCR4 were 0.75 nM and 18 nM, respectively. AMD 3465 also effectively inhibited X4 HIV replication (IC50, 1-10 nM), but not R5 HIV replication. |
| M2161 | Navarixin | Navarixin (SCH 527123) is a novel, selective CXCR2 receptor antagonist with IC50 of 3 nM. Navarixin (SCH 527123) has Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly. |
| M2041 | WZ 811 | WZ811 is a highly competitive CXCR4 antagonist with oral activity. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated regulation of cAMP level (EC50=1.2 nM) and SDF-1-induced matrix glue invasion (EC50=5.2 nM) in cells. |
| M56175 | Elubrixin | Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
| M56174 | VUF 11222 | VUF 11222 is a CXCR3 non-peptide-like agonist. |
| M56173 | (±)-AMG 487 | (±)-AMG 487 is a racemate of AMG 487. |
| M56172 | Elubrixin tosylate | Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
| M56171 | Elubrixin hydrochloride | Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. |
| M54418 | FC131 TFA | FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. |
| M54296 | CTCE-0214 | CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. |
| M53909 | TC14012 | TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. |
| M53208 | CXCR4 antagonist 4 | CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM). |
| M53207 | Ac-Pro-Gly-Pro-OH | Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as CXCR2 agonist. |
| M53205 | vMIP-II (1-21) | vMIP-II (1-21) is a CXCR4 antagonist. |
| M53204 | Antileukinate | Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). |
| M53202 | Peptide R | Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. |
| M45213 | ABSK081 | ABSK081 is an orally bioavailable CXCR4 modulator for cancer-related studies. |
| M41801 | DOTA-CXCR4-L | DOTA-CXCR4-L is a CXCR4 targeting peptide. |
| M41799 | CXCR4-IN-1 | CXCR4-IN-1 is a CXCR4 inhibitor (IC50: 20 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
